MediciNova is no longer a story about whether a tiny La Jolla developer can finish its late-stage ALS trial. Enrollment in COMBAT-ALS is complete, last visits in the companion metabolic study are complete, and the remaining work is data. The equity is a dual-binary clinical option sitting on a debt-free cash pile and a six-person operating model that has spent two decades recycling two licensed small molecules across neurology and fibrosis. What changed this year is that both near-term readouts left the recruitment phase and entered the readout window, which is why the share price doubled in four sessions into mid-September without a disclosed financing.
The load-bearing print is still the ALS study, not the income statement. Service revenue from the Mayo expanded-access collaboration is incidental. First-half research spending fell as the company stopped paying for enrollment-heavy work and waited on already-randomized patients. Cash at mid-year was $25 million. Management states that working capital funds operations at least through November 2027. That runway covers the ALS data event if burn stays near the historical twelve-million annual pace. The market capitalization of about $163 million ascribes well over one hundred million of option value to two unapproved molecules after subtracting cash.
The counterargument is that ibudilast has already been tested in multiple neurologic settings without producing an approved product, and a forty-patient metabolic study cannot carry a nine-figure enterprise value on its own. The next several months resolve whether COMBAT-ALS shows a clean functional and survival signal on the global-rank primary endpoint, whether the metabolic study produces a partnerable lipid and liver-fat package, and whether the unused Lucid sales agreement stays unused. Does the bid into the data window price a real registrational ALS asset, or only a cash-backed lottery ticket that just got more expensive?